PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34196005-1	2021	Selumetinib (ARRY-142886), an oral, potent and highly selective allosteric MEK1/2 inhibitor, is approved by the US FDA for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas.	AZD 6244	0-11	neurofibromin 1	Homo sapiens	187-211	
34196005-1	2021	Selumetinib (ARRY-142886), an oral, potent and highly selective allosteric MEK1/2 inhibitor, is approved by the US FDA for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas.	AZD 6244	13-24	neurofibromin 1	Homo sapiens	187-211